简介:【摘要】目的 研究不同剂量阿托伐他汀治疗冠心病的疗效和安全性。 方法 选取我院在 2019 年 4 月至 2020 年 4 月收治的 160 例冠心病患者,随机将其分为两组, 80 例 / 组,两组患者均用阿托伐他汀治疗,给药剂量不同。对照组患者的给药剂量为 20mg/d ,观察组的给药剂量为 40mg/d ,比较两种不同给药剂量的治疗有效性和安全性。 结果 观察组的治疗总有效率显著高于对照组,差异显著;两组患者的不良反应发生率比较,无明显差异。 结论 采用 40mg/d 阿托伐他汀治疗冠心病更有利于改善患者的心功能,且未明显增加患者用药期间的不良反应症状,临床上可综合患者的病情严重程度选择适宜的给药剂量。
简介: 【摘要】目的:探究地高辛加倍他乐克用于治疗充血性心衰伴快速房颤的临床观察。方法:选择我院 2018年 3月至 2019年 3月收治的 78例充血性心衰伴快速房颤患者,采取随机分组的方法将患者分为对照组和实验组,每组 39例,所有患者在入院前均接受常规急救和护理,对照组患者将给予地高辛治疗,实验组患者将给予地高辛加倍他乐克治疗。然后对两组患者在治疗后的心率、左心室射血分数( LVEF)和总有效率进行对比。结果:在临床经过对比后发现,对照组患者的心率为( 89.3±11.4)次 /min,实验组患者的心率为( 78.6±8.9)次 /min,实验组患者在治疗后心率改善明显高于对照组,差异具有统计学意义( P<0.05) ;对照组患者的 LVEF( 43.1±2.3) %,实验组患者的 LVEF( 52.2±2.3) %,实验组患者的 LVEF相对于对照组更加接近正常水平,差异具有统计学意义( P<0.05) ;实验组患者的治疗总有效率为 97.43%( 38),对照组患者的治疗总有效率为 79.48%( 31),实验组患者的治疗总有效率明显高于对照组,差异具有统计学意义( P<0.05)。结论:对患者使用地高辛加倍他乐克临床效果更为显著,能有效降低患者心理和改善 LVEF水平,且不会增加患者不良反应,用药安全性高,值得在临床中推广。 【关键词】充血性心衰 ;快速房颤 ;倍他乐克 ;地高辛 Objective: To explore the clinical observation of digoxin and metoprolol in the treatment of congestive heart failure with rapid atrial fibrillation. Methods: 78 patients with congestive heart failure with rapid atrial fibrillation in our hospital from March 2018 to March 2019 were selected and randomly divided into control group and experimental group, 39 cases in each group. All patients received routine first aid and nursing before admission. Patients in the control group were given digoxin treatment, while patients in the experimental group were given digoxin treatment. Then the heart rate, left ventricular ejection fraction (LVEF) and total effective rate of the two groups were compared. Results: after clinical comparison, it was found that the heart rate of patients in the control group was (89.3 ± 11.4) beats / min, and the heart rate of patients in the experimental group was (78.6 ± 8.9) beats / min. the improvement of heart rate in the experimental group was significantly higher than that in the control group (P < 0.05); The LVEF of the control group was (43.1 ± 2.3)%, and that of the experimental group was (52.2 ± 2.3)%. The LVEF of the experimental group was closer to the normal level compared with the control group (P < 0.05); The total effective rate of the experimental group was 97.43% (38), and that of the control group was 79.48% (31). The total effective rate of the experimental group was significantly higher than that of the control group (P < 0.05). Conclusion: the clinical effect of digoxin double taloc is more significant, which can effectively reduce the psychological status of patients and improve the level of LVEF, and will not increase the adverse reactions of patients, so it is worthy of clinical promotion.
简介: 【摘 要】目的:探究他克莫司与环磷酰胺治疗狼疮性肾炎的的效果和用药不良反应率。方法:纳入观察对象 40例(均确诊为狼疮性肾炎)进行实验研究,研究时间从 2015年 3月直至 2019年 5月。采用随机分组法,将观察对象分为甲乙两组,甲组 20例患儿使用他克莫司治疗,乙组 20例患儿采取环磷酰胺治疗。观察对比两组患儿治疗效果、不良反应发生情况。结果:甲组中 1例患儿疗效不明显,另外 19例均有改善,总有效率 95%;乙组中 5例疗效不明显, 1例病情恶化,另外 14例病情改善,总有效率 70%,两组间进行比较后得到 P<0.05。治疗后随访观察到,甲组患儿 1例出现尿痛的不良反应,乙组中有 6例,两组不良反应发生率的差异显著( P<0.05)。结论:狼疮性肾炎患儿在治疗过程中可应用他克莫司与环磷酰胺进行治疗,对比发现,他克莫司可以明显提升治疗的有效率,并且控制了患儿不良反应的出现,治疗安全性得到保障,临床应用效果理想,值得推广。 【关键词】他克莫司 ;环磷酰胺 ;狼疮性肾炎 ;效果 ;不良反应率 [Abstract] Objective: To explore the effect and adverse reaction rate of tacrolimus and cyclophosphamide in the treatment of lupus nephritis. Methods: 40 patients (all diagnosed as lupus nephritis) were included in the experimental study. The study period was from March 2015 to may 2019. The observation objects were randomly divided into two groups, group A (20 cases) was treated with tacrolimus, and group B (20 cases) was treated with cyclophosphamide. The treatment effect and adverse reactions of the two groups were observed and compared. Results: in group A, the curative effect of 1 case was not obvious, the other 19 cases were improved, the total effective rate was 95%; in group B, the curative effect was not obvious in 5 cases, 1 case was deteriorated, the other 14 cases were improved, the total effective rate was 70%, the comparison between the two groups showed that P < 0.05. After treatment, 1 case of adverse reactions occurred in group A and 6 cases in group B. There was a significant difference in the incidence of adverse reactions between the two groups (P < 0.05). Conclusion: tacrolimus and cyclophosphamide can be used in the treatment of children with lupus nephritis. Compared with cyclophosphamide, tacrolimus can significantly improve the efficiency of treatment, and control the occurrence of adverse reactions in children. The safety of treatment is guaranteed and the clinical application effect is ideal, which is worthy of promotion.
简介: [摘要 ] 目的 探讨乌司他丁在重症病毒性肺炎免疫调节治疗的临床疗效。 方法 回顾性分析 2017年 1月— 2019年 12月我院重症医学科收治的重症病毒性肺炎患者的临床资料,分析乌司他丁对患者免疫及预后的影响。结果 纳入 74例重症病毒性肺炎患者,死亡 19例( 25.7%) ;治疗组 36例,第 7天 CRP( 46.2±32.8) mmol/L、 HLA-DR( 60.02±12.08) %、 T-CD4+( 422±87) cell/L与第 0天的( 123±59.8) mmoL/L、( 41.22±15.90) %、( 220±54) cell/L间差异有统计学意义( P<0.05),且与对照组的( 34.1±11.8) mmol/L、( 42.06±14.08) %、( 326±69) cell/L间差异有统计学意义( t=1.781、 2.603、 2.527, P<0.05)。治疗组 28 d死亡 9例( 25.0%), VAP发生率为 21.77‰,低于对照组的 10例( 26.3%)( χ2=4.432, P=0.028)、 42.12%( χ2=0.017, P=0.897)。 结论 乌司他丁能改善重症病毒性肺炎患者的免疫功能,降低 VAP发生率,但无法改善预后。 [关键词 ] 重症病毒性肺炎 ;免疫干预 ;乌司他丁 [Abstract] Objective To investigate the clinical efficacy of ulinastatin in immunomodulatory therapy of severe viral pneumonia. Methods the clinical data of patients with severe viral pneumonia admitted to our hospital from January 2017 to December 2019 were retrospectively analyzed, and the effect of ulinastatin on immunity and prognosis of patients was analyzed. Results 74 patients with severe viral pneumonia were included, 19 (25.7%) died; There are 36 patients in the treatment group of 36 patients in the treatment group of 36 patients in the treatment group of 36 patients in the seventh day of CRP (46.2 ± 32.8) mmol / L, HLA-DR (60.02 ± 12.08), t-cd4 + (422 ± 87 ± 87) cell / L on the seventh day and (123 ± 59.8) mmol / L, (41.22 ± 15.90)%, (220 ± 54) cell / L (P < 0.05), and there are statistically significant differences between (34.1 ± 11.8) mmol / L, (42.06 ± 14.08)%, (326 ± 69) cell / L / L of the control group (t = 1.1.1.1.1.1.8) mmol / L, (42.06 ± 14.08 ± 14.08)%, (326 ± 69 781 2.603、 2.527, P<0.05)。 The incidence of VAP in the treatment group was 21.77 ‰, which was lower than that in the control group (26.3%) (χ 2 = 4.432, P = 0.028) and 42.12% (χ 2 = 0.017, P = 0.897). Conclusion Ulinastatin can improve the immune function of patients with severe viral pneumonia, reduce the incidence of VAP, but can not improve the prognosis.